Related references
Note: Only part of the references are listed.Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Ping Liu et al.
BMC GENOMICS (2022)
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Daniele Fanale et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Tumor-Derived Exosomes in Tumor-Induced Immune Suppression
Qiongyu Hao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer
Xuan Lin et al.
TRANSLATIONAL ONCOLOGY (2022)
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
Rami Vanguri et al.
GYNECOLOGIC ONCOLOGY REPORTS (2022)
Immune-and Metabolism-Associated Molecular Classi?cation of Ovarian Cancer
Zhenyue Chen et al.
FRONTIERS IN ONCOLOGY (2022)
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Aiping Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)
Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer
Shibo Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
Danian Dai et al.
FRONTIERS IN ONCOLOGY (2021)
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
Racheal Louise Johnson et al.
CANCERS (2021)
Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
Janina Swiderska et al.
CANCERS (2021)
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
Laure Chardin et al.
FRONTIERS IN ONCOLOGY (2021)
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Daniele Fanale et al.
CANCERS (2021)
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalil Khalaf et al.
FRONTIERS IN IMMUNOLOGY (2021)
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
M. Bono et al.
ESMO OPEN (2021)
PD-L1 Expression in Different Segments and Histological Types of Ovarian Cancer According to Lymphocytic Infiltrate
Ljubisa Jovanovic et al.
MEDICINA-LITHUANIA (2021)
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC)
Mayada Saad Farrag et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2021)
Tumor-Associated Macrophages: Recent Insights and Therapies
Jiawei Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
Lorena Incorvaia et al.
CANCERS (2020)
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Marek Nowak et al.
CELLS (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
The tumor microenvironment
Nicole M. Anderson et al.
CURRENT BIOLOGY (2020)
Inflammation and immunity in ovarian cancer
Diego Salas-Benito et al.
EJC SUPPLEMENTS (2020)
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
Anders Handrup Kverneland et al.
Oncotarget (2020)
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Chang Yang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis
Jiatao Hao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Epidemiology of ovarian cancer
Patricia Gaona-Luviano et al.
CHINESE CLINICAL ONCOLOGY (2020)
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Erik Henke et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti et al.
CELLULAR IMMUNOLOGY (2019)
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma
Christopher B. Morse et al.
GYNECOLOGIC ONCOLOGY (2019)
Epithelial ovarian cancer
Stephanie Lheureux et al.
LANCET (2019)
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
The Role of the Thymus in the Immune Response
Puspa Thapa et al.
THORACIC SURGERY CLINICS (2019)
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Ben Wylie et al.
CANCERS (2019)
1018PTumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study
S Giovannoni et al.
ANNALS OF ONCOLOGY (2019)
Engineering dendritic cell vaccines to improve cancer immunotherapy
Caleb R. Perez et al.
NATURE COMMUNICATIONS (2019)
Productive Cross-Talk with the Microenvironment: A Critical Step in Ovarian Cancer Metastasis
Mohamed A. Abd El Aziz et al.
CANCERS (2019)
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Lorena Incorvaia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
David W. Doo et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications
Aya S. Khairallah et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Elham Azizi et al.
CELL (2018)
Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
Venus Dalal et al.
CLINICA CHIMICA ACTA (2018)
TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
Laia Caja et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer
Maureen L. Drakes et al.
JOURNAL OF OVARIAN RESEARCH (2018)
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
Verena Wieser et al.
Oncotarget (2018)
Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer
James Scurry et al.
GYNECOLOGIC ONCOLOGY (2018)
Review of Immune Therapies Targeting Ovarian Cancer
Cong (Ava) Fan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Dmitrij Ostroumov et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo et al.
CLINICAL CANCER RESEARCH (2017)
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
Xinxin Zhu et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
Jun Li et al.
ONCOTARGET (2017)
Immune Cell Population in Ovarian Tumor Microenvironment
Dong Li Cai et al.
JOURNAL OF CANCER (2017)
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode et al.
JAMA ONCOLOGY (2017)
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Thomas Worzfeld et al.
FRONTIERS IN ONCOLOGY (2017)
Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer
Fiona R. James et al.
BMC CANCER (2017)
Pre-metastatic niches: organ-specific homes for metastases
Hector Peinado et al.
NATURE REVIEWS CANCER (2017)
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients
Till Adhikary et al.
BMC GENOMICS (2017)
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Maartje C. A. Wouters et al.
CLINICAL CANCER RESEARCH (2016)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb-Esfahani et al.
ONCOTARGET (2016)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Bohm et al.
CLINICAL CANCER RESEARCH (2016)
Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
David R. Kroeger et al.
CLINICAL CANCER RESEARCH (2016)
Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer
Phillip P. Santoiemma et al.
GYNECOLOGIC ONCOLOGY (2016)
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
John R. Webb et al.
GYNECOLOGIC ONCOLOGY (2016)
Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer
Hans-Christian Boesmueller et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Veronica Rojas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Immuno-oncologists eye up macrophage targets
Chris Morrison
NATURE REVIEWS DRUG DISCOVERY (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Tumor Infiltrating Lymphocytes in Ovarian Cancer
Maria Luisa Gasparri et al.
Asian Pacific Journal of Cancer Prevention (2015)
Tumor infiltrating lymphocytes in ovarian cancer
Phillip P. Santoiemma et al.
CANCER BIOLOGY & THERAPY (2015)
Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer
Keith L. Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Efficient molecular subtype classification of high-grade serous ovarian cancer
Huei San Leong et al.
JOURNAL OF PATHOLOGY (2015)
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino et al.
NATURE (2015)
Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis
Miranda Y. Fong et al.
NATURE CELL BIOLOGY (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Immunotherapeutic approaches to ovarian cancer treatment
Cariad Chester et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.
Kyle Strickland et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
Andrea Varga et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
John R. Webb et al.
CLINICAL CANCER RESEARCH (2014)
The immune contexture of primary and metastatic human tumours
Nicolas A. Giraldo et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells
Francesca Bellora et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
Wim de Lau et al.
GENES & DEVELOPMENT (2014)
Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse
Silke Reinartz et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism
Jianqun Liao et al.
PLOS ONE (2014)
Analysis of FoxP3+T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers
Cecilia Hermans et al.
PLOS ONE (2014)
Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response
Chih-Long Chang et al.
CANCER RESEARCH (2013)
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
Joshy George et al.
CLINICAL CANCER RESEARCH (2013)
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
Sergio Marchini et al.
EUROPEAN JOURNAL OF CANCER (2013)
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche
Andrea Flesken-Nikitin et al.
NATURE (2013)
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment
Michael H. Kershaw et al.
ONCOIMMUNOLOGY (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability
Anil Aysal et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Prediction of BRCA1 Germline Mutation Status in Women With Ovarian Cancer Using Morphology-based Criteria Identification of a BRCA1 Ovarian Cancer Phenotype
Mika Fujiwara et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Samar Masoumi Moghaddam et al.
CANCER AND METASTASIS REVIEWS (2012)
Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
Gulsun Erdag et al.
CANCER RESEARCH (2012)
CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer
Julie S. Nielsen et al.
CLINICAL CANCER RESEARCH (2012)
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Wei-Ting Hwang et al.
GYNECOLOGIC ONCOLOGY (2012)
The peritoneal tumour microenvironment of high-grade serous ovarian cancer
D. Andrew Leinster et al.
JOURNAL OF PATHOLOGY (2012)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A. Soslow et al.
MODERN PATHOLOGY (2012)
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
Jessica N. McAlpine et al.
MODERN PATHOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Tumor immune surveillance and ovarian cancer Lessons on immune mediated tumor rejection or tolerance
Lana E. Kandalaft et al.
CANCER AND METASTASIS REVIEWS (2011)
Immunity and immune suppression in human ovarian cancer
Claudia C. Preston et al.
IMMUNOTHERAPY (2011)
Immunotherapy for Ovarian Cancer: What's Next?
Lana E. Kandalaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy
Pravin Mishra et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
The Role of Tumor Stroma in Cancer Progression and Prognosis Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer
Roy M. Bremnes et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
Xia Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Ovarian cancer creates a suppressive microenvironment to escape immune elimination
Refika Yigit et al.
GYNECOLOGIC ONCOLOGY (2010)
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
Xiaoyuan Huang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Ilona Kryczek et al.
BLOOD (2009)
Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes
M. Stumpf et al.
BRITISH JOURNAL OF CANCER (2009)
Intraepithelial T Cells and Tumor Proliferation
Sarah F. Adams et al.
CANCER (2009)
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
Ninke Leffers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Angiogenesis and ovarian cancer
Cesar Gomez-Raposo et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
G. Gorfu et al.
CURRENT MOLECULAR MEDICINE (2009)
Paclitaxel and immune system
Aqeel Javeed et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Marketa Tomsova et al.
GYNECOLOGIC ONCOLOGY (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
Dorothee Duluc et al.
BLOOD (2007)
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
Elizabeth A. Manning et al.
CLINICAL CANCER RESEARCH (2007)
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2007)
Local interferon-α gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster
Hidehiko Hara et al.
CANCER SCIENCE (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: Identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy
Caroline Bouzin et al.
JOURNAL OF IMMUNOLOGY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
HP Dong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Regulatory T cells in ovarian cancer: Biology and therapeutic potential
B Barnett et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2005)
The role of IL-6 and STAT3 in inflammation and cancer
DR Hodge et al.
EUROPEAN JOURNAL OF CANCER (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)